CREST Trial Marks New Era for High-Risk NMIBC: Dr. Gordon Brown on IO-BCG Combinations

Gordon Brown, DO, Summit Health, breaks down the CREST trial results in high-risk NMIBC, highlighting the benefits of combining sasanlimab with BCG and the potential for a paradigm shift in treatment.

He also previews upcoming trials like POTOMAC and KEYNOTE-676 that could further reshape the standard of care.

Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Conference Coverage

Live meeting highlights

Zachary BessetteLocalized | May 29, 2025
A novel algorithm identifies patients with high-risk non-metastatic PCa who may benefit from second-generation ARPIs.
Emily MenendezAdvanced Urothelial Carcinoma | May 28, 2025
Nivolumab + ipilimumab provided a favorable landmark OS in cisplatin-ineligible patients with unresectable or metastatic UC.
Emily MenendezRLT | May 29, 2025
The addition of ipi/nivo to LuPSMA improved PSA-PFS over 12 months in patients with mCRPC.
Karine Tawagi, MDProstate Cancer | May 27, 2025
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on ARANOTE, Metacure, and more.